home
portfolio
approach
team
careers
news
contact
investor portal
home
portfolio
approach
team
careers
news
contact
investor portal
Nextech Invest
C4 Therapeutics to Advance CFT8919, a Selective Degrader of EGFR L858R, into IND-Enabling Studies
C4 Therapeutics to Advance CFT8919, a Selective Degrader of EGFR L858R, into IND-Enabling Studies
Post navigation
Previous Post
Previous
Kronos Bio Announces Participation in Upcoming Investor Conferences
Next Post
Next
IconOVir Bio to Present at Jefferies Healthcare Conference